In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT +1.14%), Johnson & Johnson (JNJ +0.94%), Sanofi (SNY +0.46%), Pfizer (PFE -0.80%), and Merck (MRK -3.21%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.